



European  
Reference  
Network

# ReCONNECT

First International Congress  
on rare and low-prevalence  
connective tissue and  
musculoskeletal diseases

Brussels 20-22 April 2023

Preliminary programme

On behalf of the Congress Committee, it is a great pleasure to invite you to take part to the first ERN ReCONNECT International Congress on rare and low-prevalence connective tissue diseases which will take place in Brussels, Belgium, on April 20-22, 2023.

Knowledge, awareness and a patient-centred approach have been cornerstones of the activity of ERN ReCONNECT, the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases, in its first five years of activity and the programme reflects the ERN mission, covering important topics in the diagnosis and management of rare and complex diseases such epidemiology, diagnosis and clinical management, biobanking and registries, quality.

The programme has been developed to integrate the perspective of the different stakeholders involved in rare diseases management. For this reason we expect that the congress will be of interest not only for specialists but also for people living with a rare disease, caregivers, clinicians, policy makers, industry, and will represent an opportunity for rare and complex connective tissue diseases community to meet, work together and find new inspirations for research, diagnosis and therapy.

We are excited about meeting you at this innovative conference that, we hope, will stimulate and foster collaborations all around Europe! Therefore, we warmly invite to present and share original and significant experience, research and innovation in the field of rare and complex connective tissue diseases.

We are looking forward to welcoming you in Brussels.

*Marta Mosca on behalf of the Congress Committee*



Congress Committee

### Chairperson of the Congress

Marta Mosca, Italy

### International Scientific Committee

Silvia Aguilera, Spain  
Janette Andersen, Denmark  
Stefano Bombardieri, Italy  
Coralie Bouillot, Switzerland  
Camelia Bucă, Romania  
Gerd R. Burmester, Germany  
Sara Cannizzo, Italy  
Patricia E. Carreira, Spain  
Eva Collado-González, Spain  
Alain Cornet, Belgium

Maurizio Cutolo, Italy  
Andrea Doria, Italy  
Ilaria Fagiolini, Italy  
Sue Farrington, UK  
João Eurico Fonseca, Portugal  
Charissa Frank, Belgium  
Andrea Gaglioti, Italy  
Ilaria Galetti, Italy  
Vera Guimarães, Portugal  
Eric Hachulla, France

Frédéric Houssiau, Belgium  
Diana Marinello, Italy  
Lisa Matthews, UK  
Christophe Richez, France  
Matthias Schneider, Germany  
Vanessa Smith, Belgium  
Rosaria Talarico, Italy  
Jacob van Laar, The Netherlands  
Ana Vieira, Portugal  
Madelon Vonk, The Netherlands



European  
Reference  
Network

**ERN ReCONNECT Coordination Team**  
Via Roma, 67  
56126 Pisa, Italy  
[ern.reconnect@ao-pisa.toscana.it](mailto:ern.reconnect@ao-pisa.toscana.it)  
<https://reconnect.ern-net.eu>

**13:00 - 14:00    Opening ceremony**

**13:00 - 13:15    Welcome message**

M. Mosca (Pisa, Italy), M. Cutolo (Genoa, Italy)

**13:15 - 13:30    ERNs: a new paradigm in cross-border collaboration**

A. Rys (Brussels, Belgium)

**13:30 - 13:45    Patients as driving force**

TBD

**13:45 - 14:00    Overview and mission of ERN ReCONNECT. Overview on the rCTDs.**

M. Mosca (Pisa, Italy)

**14:00 - 15:20    Epidemiology of rCTDs**

Chairs: J. Andersen (Knebel, Denmark), M. Mosca (Pisa, Italy), V. Smith (Gent, Belgium)

**14:00 - 14:15    Clinical practice guidelines in rare connective tissue diseases: a brook too wide for leaping?**

L. Carmona (Santiago, Spain)

**14:15 - 14:30    Prevalence of work participation in rare connective tissue diseases**

S. Decuman (Gent, Belgium)

**14:30 - 14:45    Epidemiology in the new era: is there a role for twitter and social media?**

**The case of systemic lupus erythematosus**

L. Arnaud (Strasbourg, France)



**14:45 - 15:00    Discussion**

## Sycamore Ballroom



15:00 - 15:10

### AUTOANTIBODIES AND DAMAGE IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A LONGITUDINAL MULTICENTER STUDY FROM THE MYONET INTERNATIONAL NETWORK

F. Espinosa<sup>1</sup>, K. Lodin<sup>1</sup>, M. Dastmalchi<sup>1</sup>, A. Ceribelli<sup>2</sup>, J. Venkovsky<sup>3</sup>, H. Chinoy<sup>4</sup>, L. Diederichsen<sup>5</sup>, S. Shin<sup>6</sup>, I. Lundberg<sup>1</sup>, H. Alexanderson<sup>1</sup>, Myonet contributors<sup>7</sup>  
(<sup>1</sup>Stockholm, Sweden, <sup>2</sup>Rozzano, Italy, <sup>3</sup>Prague, Czech Republic, <sup>4</sup>Manchester, United Kingdom,  
<sup>5</sup>Copenhagen, Denmark, <sup>6</sup>São Paulo, Brazil, <sup>7</sup>Myonet)



15:10 - 15:20

### CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH SYSTEMIC SCLEROSIS SINE SCLERODERMA : DATA FROM THE INTERNATIONAL EUSTAR DATABASE

A. Lescoat<sup>1</sup>, S. Huang<sup>2</sup>, P.E. Carreira<sup>3</sup>, E. Siegert<sup>3</sup>, J. de Vries-Bouwstra<sup>3</sup>, J. Distler<sup>3</sup>, V. Smith<sup>3</sup>, F. Del Galdo<sup>3</sup>, B. Anic<sup>3</sup>, N. Damjanov<sup>3</sup>, S. Rednic<sup>3</sup>, C. Ribi<sup>3</sup>, D. Farge Bancel<sup>3</sup>, A. Hoffmann-Vold<sup>3</sup>, A. Gabrielli<sup>3</sup>, O. Distler<sup>3</sup>, D. Khanna<sup>2</sup>, Y. Allanore<sup>4</sup>, E. Collaborators<sup>3</sup>  
(<sup>1</sup>Rennes, France, <sup>2</sup>Ann Arbor, USA, <sup>3</sup>Erlangen, Germany, <sup>4</sup>Paris, France)



15:20 - 15:35

### ERN ReCONNECT Points to Consider for treating ARDs patients with antiviral therapies and antibody products anti-SARS-CoV-2

R. Talarico (Pisa, Italy)

15:35 - 16:15

Coffee break and Poster session

16:15 - 17:35

### Diagnosis and clinical management of rCTDs

Chairs: S. Aguilera (Elche, Spain), E. Hachulla (Lille, France)

16:15 - 16:30

### Red flags for early diagnosis: the example of Systemic Sclerosis

V. Smith (Gent, Belgium)

## Sycamore Ballroom

16:30 - 16:45

### **Creating classification criteria for rare diseases – a 20 years retrospective**

R. Cervera (Barcelona, Spain)

16:45 - 17:00

### **Biological data to improve our ability to refine disease phenotypes and personalize treatment options for patients**

G. Burmester (Berlin, Germany)



17:00 - 17:15

### **Discussion**



17:15 - 17:25

### **INTERFERON SIGNATURE AND NEUTROPHIL EXTRACELLULAR TRAP RELEASE ARE ASSOCIATED WITH FUTURE FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS AND THROMBOTIC EVENTS IN ANTIPHOSPHOLIPID SYNDROME**

B. Geertsema-Hoeve<sup>1</sup>, L.L. van den Hoogen<sup>1,2</sup>, E.D. Kaan<sup>1</sup>, H.L. Leavis<sup>1</sup>, J.A.G. van Roon<sup>1</sup>, M. Limper<sup>1</sup>  
(<sup>1</sup>Utrecht, The Netherlands, <sup>2</sup>Nijmegen, The Netherlands)



17:25 - 17:35

### **THE ROLE OF UTERINE ARTERY DOPPLER IN PATIENTS WITH CONNECTIVE TISSUE DISEASES AND/OR ANTIPHOSPHOLIPID AUTOANTIBODIES: RESULTS FROM A COHORT OF HIGH-RISK PREGNANCIES**

D. Zucchi<sup>1,2</sup>, C. Tani<sup>2</sup>, F. Monacci<sup>2</sup>, C. Ietto<sup>2</sup>, E. Elefante<sup>2</sup>, S. Gori<sup>2</sup>, V. Gelsi<sup>2</sup>, L. Carli<sup>2</sup>, F.A.L. Strigini<sup>2</sup>, M. Mosca<sup>2</sup>  
(<sup>1</sup>Siena, Italy, <sup>2</sup>Pisa, Italy)



**17:35 - 18:35**

### **Meet the experts on Ehlers-Danlos syndromes**

C. Frank (Beringen, Belgium), F. Malfait (Gent, Belgium)

18:35

### **Networking Cocktail**

**09:00 - 10:20 Biobanking and Registries**

Chairs: M. Schneider (Düsseldorf, Germany), A. Strangfeld (Berlin, Germany)

**09:00 - 09:15 Biobanking and registries why we need them and what we are doing**

J.E. Fonseca (Lisbon, Portugal)

**09:15 - 09:30 FAIR principles in registries and biobanking**

A. Rodrigues (Lisbon, Portugal)

**09:30 - 09:45 The role of patients to help building ERN registries**

R. Wheeler (Hockley, UK)



**09:45 - 10:00 Discussion**



**10:00 - 10:10 LUPUSNET - A FEDERATED MODEL/NETWORK TO SUPPORT REAL-WORLD DATA RESEARCH IN SYSTEMIC LUPUS ERYTHEMATOSUS**

J. Schreiber<sup>1</sup>, M. van Speybroeck<sup>2</sup>, W. Noël<sup>3</sup>, T.A. Simon<sup>4</sup>, F. Lavie<sup>5</sup>  
(<sup>1</sup>Neuss, Germany, <sup>2</sup>Beerse, Belgium, <sup>3</sup>Flemish Brabant, Belgium, <sup>4</sup>New Jersey, USA, <sup>5</sup>Paris, France)



**10:10 - 10:20 QUALITY INDICATORS FOR SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A PORTUGUESE CENTER**

M. Villander<sup>1,2</sup>, A. Afonso<sup>1</sup>, L. Monteiro Dias<sup>1</sup>, A. Leal Brito<sup>1</sup>, M. Lemos Mendes<sup>1</sup>, C. Sarteschi<sup>2</sup>, L. Vasconcelos<sup>2</sup>, D. G. Oliveira<sup>1</sup>, F. Farinha<sup>1</sup>, R. Faria<sup>1</sup>, A. Marinho<sup>1</sup>, C. Vasconcelos<sup>1</sup>  
(<sup>1</sup>Porto, Portugal, <sup>2</sup>Recife, Brazil)

**10:20 - 11:40 Coffee break and Poster Session**



## Sycamore Ballroom

11:40 - 13:00

### Quality of life of rCTDs

Chairs: T. Alexander (Berlin, Germany), C. Bouillot (Paris, France)

11:40 - 11:55

### Midnight winter's tales of rare disease

S. Aguilera (Elche, Spain), E. Collado-Gonzales (Murcia, Spain), I. Galetti (Brescia, Italy), V. Guimarães (Lisbon, Portugal), R. Talarico (Pisa, Italy)

11:55 - 12:10

### Mastering resilience

L. Kwakkenbos (Nijmegen, The Netherlands)

12:10 - 12:25

### Therapeutic education in rare and complex diseases patients: the yellow brick road

E. Hachulla (Lille, France), M. Farhat (Lille, France)



12:25 - 12:40

### Discussion



12:40 - 12:50

### HEALTH-RELATED QUALITY OF LIFE: THE MAIN DETERMINANT OF PATIENT-PHYSICIAN DISCORDANCE IN GLOBAL DISEASE SEVERITY ASSESSMENT OF RARE AND COMPLEX CONNECTIVE TISSUE DISEASES

G. Fulvio, F. Trentin, E. Elefante, S. Fonzetti, M. Da Rio, C. Cigolini, D. Schilirò, M. Maffi, L. Scagnellato, A. Valevich, F. Fattorini, I.C. Navarro Garcia, F. D'Alessandro, G. De Mattia, A. Gaglioti, G. Andreozzi, V. Lorenzoni, C. Carmassi, C. Tani, M. Mosca (Pisa, Italy)



12:50 - 13:00

### THE LONG-TERM COURSE OF THE HEALTH ASSESSMENT QUESTIONNAIRE IN PATIENTS WITH SYSTEMIC SCLEROSIS

S. Liem<sup>1</sup>, S. Bergstra<sup>1</sup>, J. Ciaffi<sup>1,2</sup>, C. van der Meulen<sup>1</sup>, D. Ueckert<sup>1</sup>, M. Schriemer<sup>3</sup>, T. Huizinga<sup>1</sup>, T. Vliet Vlieland<sup>1</sup>, J. de Vries-Bouwstra<sup>1</sup>

(<sup>1</sup>Leiden, The Netherlands, <sup>2</sup>Bologna, Italy, <sup>3</sup>Utrecht, The Netherlands)



European  
Reference  
Network

# ReCONNECT

Programme

Sycamore Ballroom

13:00 - 14:00 Lunch

**14:00 - 15:20 Organisational and economic aspects of rCTDs**

Chairs: A. Rys (Brussels, Belgium), D. Taruscio (Rome, Italy)

**14:00 - 14:15 Why does organisation matter in rare diseases?**

G. Turchetti (Pisa, Italy)

**14:15 - 14:30 Re-designing care for rCTDs through patient's care pathways**

D. Marinello (Pisa, Italy), R. Talarico (Pisa, Italy)

**14:30 - 14:45 Access to care and rare diseases: a new scenario for rare diseases**

F. Houjéz (Paris, France)



14:45 - 15:00 **Discussion**



**15:00 - 15:10 THE JOURNEY OF PREGNANCY IN RARE AND COMPLEX CONNECTIVE TISSUE DISEASES: THE NURSE'S PERSPECTIVE**


S. Gori, D. Zucchi, E. Elefante, F. Monacci, C. Letto, V. Gelsi, L. Carli, C. Tani, M. Mosca (Pisa, Italy)



**15:10 - 15:20 THE IMPORTANCE OF SOCIAL MEDIA IN RCTDS: A LOOK INTO REGIONAL, NATIONAL AND EUROPEAN SLE ORGANISATIONS AND FEDERATIONS**

S. Aguilera<sup>1</sup>, N. Zuniga-Serrano<sup>2</sup>  
(<sup>1</sup>Elche, Spain, <sup>2</sup>Madrid, Spain)

15:20 - 15:50 Coffee break



Sycamore Ballroom

15:50 - 17:10

**Therapeutic management of rCTDs**

Chairs: V. Guimarães (Lisbon, Portugal), M. Mosca (Pisa, Italy), M. Schneider (Düsseldorf, Germany)

15:50 - 16:05

**Adherence to therapy in rare and complex diseases. From the dimension of the problem to the development of specific strategies to reduce non-adherence.**

R. Talarico (Pisa, Italy)

16:05 - 16:20

**Fatigue, quality of life and patients' perspectives: are these aspects sufficiently considered in the management of patients with rare and complex diseases?**

M. Schneider (Düsseldorf, Germany)

16:20 - 16:35

**The clinical patient management system: only an opportunity for cross-border consultations?**

J.M. van Laar (Utrecht, The Netherlands)



16:35 - 16:50

**Discussion**



16:50 - 17:00

**REAL-LIFE MULTICENTRIC NATIONAL OBSERVATIONAL STUDY OF THE USE OF NINTE DANIB IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE**

V. Koether<sup>1</sup>, D. Launay<sup>1</sup>, M. Reynaud Gaubert<sup>2</sup>, G. Prevot<sup>3</sup>, L. Mouthon<sup>4</sup>, R. Borie<sup>4</sup>, K. El Husseini<sup>4</sup>, P. Decker<sup>5</sup>, S. Dirou<sup>6</sup>, E. Blanchart<sup>1</sup>, A. Leurs<sup>1</sup>, S. Berthier<sup>1</sup>, X. Delbrel<sup>1</sup>, M. Durel<sup>1</sup>, C. Agard<sup>1</sup>, A. Nieves<sup>2</sup>, E. Hachulla<sup>1</sup>, D. Aydindag<sup>7</sup>, V. Cottin<sup>7</sup>, Y. Uzunhan<sup>4</sup>

(<sup>1</sup>Lille, France, <sup>2</sup>Marseille, France, <sup>3</sup>Toulouse, France, <sup>4</sup>Paris, France, <sup>5</sup>Nancy, France,

<sup>6</sup>Nantes, France, <sup>7</sup>Lyon, France)



European  
Reference  
Network

# ReCONNECT

Programme

Sycamore Ballroom



17:00 - 17:10

**MUSCLE FIBRES PLAY A CRITICAL ROLE IN THE THERAPEUTIC RESPONSE OF MYOSITIS TO GLUCOCORTICOIDS THROUGH POLARISATION OF THE INFLAMMATORY INFILTRATE BY A PARACRINE MECHANISM**

M. Giannini, D. Rovito, L. Debrut, C. Keime, A.L. Charles, D. Duteil, B. Geny, D. Metzger, G. Laverny, A. Meyer  
(Strasbourg, France)



17:10 - 18:10

**Meet the experts**

**Pregnancy in rare and complex connective tissue diseases: patients and physicians point of view**  
M. Mosca (Pisa, Italy)

**09:00 - 10:20 Comorbidities**

Chairs: M. Cutolo (Genoa, Italy), J.E. Fonseca (Lisbon, Portugal)

**09:00 - 09:15 Cardio-vascular comorbidities in rare connective tissue diseases**

S. Jacobsen (Copenhagen, Denmark)

**09:15 - 09:30 Covid-19 syndrome an exclusive comorbidity of the last 3 years and unique lesson for the ERN ReCONNECT patients**

P. Machado (Louvain, Belgium)

**09:30 - 09:45 Living with a rare connective disease: not only active disease, but also comorbidities.  
The need of a holistic approach.**

S. Aguilera (Elche, Spain)



**09:45 - 10:00 Discussion**



**10:00 - 10:10 LONG-TERM OUTCOMES OF COVID-19 VACCINATION IN PATIENTS WITH RARE AND COMPLEX CONNECTIVE TISSUE DISEASES: THE ERN-RECONNECT VACCINATE STUDY**

C. Cardelli<sup>1,2</sup>, C. Tani<sup>1</sup>, G. Casciarano<sup>1</sup>, M. Diomedi<sup>1</sup>, L. Gualtieri<sup>1</sup>, R. Depascale<sup>3</sup>, A. Gamba<sup>3</sup>, L. Iaccarino<sup>3</sup>, A. Doria<sup>3</sup>, M.J.S. Bandeira<sup>4</sup>, S. Paiva Dinis<sup>4</sup>, V.C. Romão<sup>4</sup>, E. Gotelli<sup>5</sup>, S. Paolino<sup>5</sup>,

M. Cutolo<sup>5</sup>, N. Di Giosaffatte<sup>6</sup>, A. Ferraris<sup>6</sup>, P. Grammatico<sup>6</sup>, L. Cavagna<sup>7</sup>, V. Codullo<sup>7</sup>

(<sup>1</sup>Pisa, Italy, <sup>2</sup>Siena, Italy, <sup>3</sup>Padua, Italy, <sup>4</sup>Lisbon, Portugal, <sup>5</sup>Genoa, Italy, <sup>6</sup>Rome, Italy, <sup>7</sup>Pavia, Italy)

## Sycamore Ballroom



10:10 - 10:20

### **THE ROLE OF ASYMMETRIC DIMETHYLARGININE IN ENDOTHELIAL DYSFUNCTION IN SYSTEMIC SCLEROSIS**

T. Dimitroulas, E. Pagkopoulou, S. Soulaidopoulou  
(Thessaloniki, Greece)

10:20 - 10:50

Coffee break

**10:50 - 12:10**

### **Innovative approach of clinical studies in rCTDs**

Chairs: V. Smith (Gent, Belgium), A. Vieira (Lisbon, Portugal)

10:50 - 11:05

### **How and when could patients be effectively involved in the development of RCTs?**

I. Galetti (Brescia, Italy)

11:05 - 11:20

### **Does localized acute and chronic pain requests careful evaluation before any therapeutical approach?**

M. Cutolo (Genoa, Italy)

11:20 - 11:35

### **Innovative type studies for rare diseases: how to run studies and how to gather real world evidence data**

K. Brown-Plueschke (Amsterdam, The Netherlands)



11:35 - 11:50

Discussion

## Sycamore Ballroom



11:50 - 12:00

### DOES EARLY IMMUNOSUPPRESSIVE THERAPY PREVENT SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE?

A. Velauthapillai<sup>1</sup>, M.F.R Bootsma<sup>1</sup>, C. Bruni<sup>2</sup>, O. Distler<sup>2</sup>, C.H.M. van den Ende<sup>1</sup>, M.C. Vonk<sup>1</sup>  
(<sup>1</sup>Nijmegen, The Netherlands, <sup>2</sup>Zürich, Switzerland)



12:00 - 12:10

### EFFICACY AND SAFETY OF ABATACEPT IN IGG4-RELATED DISEASE: A CLINICAL AND IMMUNO-PATHOLOGICAL PILOT STUDY


J. Mahajne, C. Minici, M. Lanzillotta, G. Di Colo, T. Jofra, G. Fousteri, L. Dagna, E. Della Torre  
(Milan, Italy)

**12:10 - 13:10**

### Closing ceremony and best poster awards

13:10 - 14:15

Lunch



Thursday, 20<sup>th</sup> April 2023  
15:35 – 16:15

### POSTER SESSION 1: ORGANISATIONAL AND ECONOMIC ASPECTS, EPIDEMIOLOGY (1)

Chair: G. Turchetti (Pisa, Italy)

**PO1:01 PRODUCTIVITY ANALYSIS IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: PRELIMINARY DATA FROM A MONOCENTRIC COHORT ON THE IMPACT OF THE DISEASE BURDEN**

L. Carli<sup>1</sup>, C. Cardelli<sup>1</sup>, M. Diomedi<sup>1</sup>, E. Laurino<sup>1</sup>, F. Fattorini<sup>1</sup>, S. Barsotti<sup>2</sup>, M. Mosca<sup>1</sup>  
(<sup>1</sup>Pisa, Italy, <sup>2</sup>Livorno, Italy)

**PO1:02 PAEDIATRIC ANTIPHOSPHOLIPID SYNDROME: THE ESTIMATED PREVALENCE IN PIEDMONT AND AOSTA VALLEY AND AN UPDATED SYSTEMATIC REVIEW OF THE LITERATURE**

M. Radin, I. Cecchi, M. Arbrile, M. Cioffi, S. Foddai, A. Barinotti, E. Menegatti, S. Baldovino, S. Sciascia,  
D. Roccatello  
(Turin, Italy)

**PO1:03 FACTORS ASSOCIATED WITH ADVERSE PREGNANCY OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

C. Sieiro Santos<sup>1</sup>, R. Rego Salgueiro<sup>2</sup>, C. Moriano Morales<sup>1</sup>, C. Álvarez Castro<sup>1</sup>, E. Díez Álvarez<sup>1</sup>  
(<sup>1</sup>León, Spain, <sup>2</sup>Guarda, Portugal)

**PO1:04 IMMUNE RESPONSES TO mRNA VACCINES AGAINST SARS-COV-2 IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES**

C. Sieiro Santos, S. Calleja Antolin, E. Díez Álvarez, J. Ruiz de Morales  
(León, Spain)

**PO1:05 TAFRO SYNDROME: A PRIVILEGED AND SEVERE MANIFESTATION OF SJÖGREN'S SYNDROME? A SYSTEMATIC REVIEW**

L. Grange<sup>1</sup>, E. Chalayer<sup>1</sup>, D. Boutboul<sup>2</sup>, S. Paul<sup>1</sup>, L. Galicier<sup>2</sup>, B. Gramont<sup>1</sup>, M. Killian<sup>1</sup>  
(<sup>1</sup>Saint-Etienne, France, <sup>2</sup>Paris, France)

## POSTER SESSION 2: EPIDEMIOLOGY (2)

Chair: S. Jacobsen (Copenhagen, Denmark)

**PO2:06 PROGRESSIVE PULMONARY FIBROSIS IN CONNECTIVE TISSUE DISEASE ASSOCIATED INTERSTITIAL LUNG DISEASES**

Y. Chiu<sup>1</sup>, M. Koops<sup>1</sup>, M. Voortman<sup>1</sup>, W. van Es<sup>2</sup>, L. Langezaal<sup>2</sup>, P. Welsing<sup>1</sup>, A. Jamnitski<sup>2</sup>, J. van Laar<sup>1</sup>, J. Grutters<sup>2</sup>, J. Spierings<sup>1</sup>  
(<sup>1</sup>Utrecht, The Netherlands, <sup>2</sup>Nieuwegein, The Netherlands)

**PO2:07 EPIDEMIOLOGY OF VASCULAR PRIMARY ANTIPHOSPHOLIPID SYNDROME: A POPULATION-BASED STUDY IN A MOUNTAIN COMMUNITY IN NORTHERN ITALY**

F. Angelì<sup>1</sup>, C. Nalli<sup>1</sup>, G. Pascariello<sup>1</sup>, A. Zentilin<sup>1</sup>, E. Raffetti<sup>2</sup>, L. Andreoli<sup>1</sup>, I. Cavazzana<sup>1</sup>, C. Gasparotti<sup>1</sup>, M. Magoni<sup>3</sup>, C. Scarcella<sup>4</sup>, F. Donato<sup>1</sup>, A. Tincani<sup>1</sup>, F. Franceschini<sup>1</sup>  
(<sup>1</sup>Brescia, Italy, <sup>2</sup>Cambridge, United Kingdom, <sup>3</sup>Ryadh, Saudi Arabia, <sup>4</sup>Monza, Italy)

**PO2:08 RAYNAUD'S PHENOMENON IN SJÖGREN SYNDROME: A CROSS SECTIONAL ITALIAN MONOCENTRIC STUDY**  
E. Simoncelli, S. Colafrancesco, A. Gattamelata, R. Izzo, F. Giardina, M. Villa, L. Mastromanno, F. Conti, R. Priori (Rome, Italy)

**PO2:09 ASSOCIATION OF IGG4-RELATED DISEASE WITH OTHER IMMUNE-MEDIATED CONDITIONS**  
V. Batani, M. Lanzillotta, J. Mahajne, F. Pedica, L. Dagna, E. Della Torre (Milan, Italy)

**PO2:10 PERIODONTAL STATUS IN A GROUP OF ROMANIAN SSC PATIENTS: A PILOT STUDY**  
A. Stanomir, A. Roman, A. Soanca, I.C. Micu, A. Ciurea, S.P. Simon, M.M. Tamas, L. Damian, I. Felea, I. Filipescu, I. Szabo, N.V. Rednic, L. Muntean, T.N. Onea, C. Pamfil, S. Rednic (Cluj-Napoca, Romania)

### POSTER SESSION 3: QUALITY OF LIFE (1)

Chair: TBD

- PO3:11 DRY EYE SYMPTOMS STRONGLY CORRELATE WITH OCULAR AND EXTRAOCULAR PAIN IN PRIMARY SJÖGREN'S SYNDROME. INTERIM REPORT OF A PILOT CROSS-SECTIONAL MONOCENTRIC STUDY.**  
L. Moroni, G. Ferrari, F. Bonelli, V. Batani, M. Bellone, M. Matucci Cerinic, L. Dagna  
(Milan, Italy)
- PO3:12 AESTHETIC IMPAIRMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: A CASE CONTROL STUDY USING A SEMI-QUANTITATIVE SCALE FOR BODY IMAGE ASSESSMENT. THE SCLERO-ESTHET STUDY.**  
M. Farhat, P. Guerreschi, S. Morell-Dubois, V. Denken, J. Labreuche, S. Sanges, V. Sobanski, E. Hachulla,  
D. Launay  
(Lille, France)
- PO3:13 ASSESSMENT OF PSYCHOLOGICAL CONSEQUENCES IN PATIENTS WITH CHRONIC RHEUMATIC, SYSTEMIC AUTOIMMUNE, AND AUTOINFLAMMATORY DISEASES PRESENTED WITH COVID-19: THE MENTCOVRMD STUDY**  
M. Farhat, E. Drumez, M. Horn, S. Morell-Dubois, G. Vaiva, E. Hachulla  
(Lille, France)
- PO3:14 HEALTH RELATED QUALITY OF LIFE IN CHRONIC KIDNEY DISEASE IN A MOROCCAN POPULATION**  
W. Arache, D. El Kabbaj  
(Rabat, Morocco)
- PO3:15 HOW CAN WE IMPROVE THE QUALITY OF LIFE OF PATIENTS WITH SYSTEMIC IMMUNE-MEDIATED DISEASES?**  
S. Salvucci, E. Filippini, F. Gazzoli, L. Lucarelli, R. Santangeli, A. Festa, L. Manfredi, G. Moroncini  
(Ancona, Italy)

**POSTER SESSION 4: QUALITY OF LIFE (2)**

Chair: J. Andersen (Brussels, Belgium)

- PO4:16 THE EXPERIENCE OF PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES DURING THE COVID-19 PANDEMIC: RESULTS FROM STORIES COLLECTED THROUGH THE NARRATIVE MEDICINE APPROACH**

I. Palla, V. Lorenzoni, C. Tani, D. Marinello, M. Mosca, G. Turchetti  
(Pisa, Italy)

- PO4:17 DEVELOPMENT OF AN IGG4-RELATED DISEASE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE**

M. Lanzillotta, G. Ramirez, M. Mazzetta, A. Catarinella, V. Di Mattei, L. Dagna, E. Della Torre  
(Milan, Italy)

- PO4:18 QUALISEX QUESTIONNAIRE: CULTURAL ADAPTATION AND PRELIMINARY VALIDATION FOR ITS USE IN WOMEN WITH SJÖGREN'S SYNDROME**

M. Villa<sup>1</sup>, F. Giardina<sup>1</sup>, A. Gattamelata<sup>1</sup>, S. Colafrancesco<sup>1</sup>, L. Mastromanno<sup>1</sup>, E. Simoncelli<sup>1</sup>, F. Conti<sup>1</sup>, G. Curcio<sup>2</sup>, R. Priori<sup>1</sup>  
(<sup>1</sup>Rome, Italy, <sup>2</sup>L'Aquila, Italy)

- PO4:19 LONG-TERM NEURODEVELOPMENTAL OUTCOME OF CHILDREN BORN TO WOMEN WITH RARE AUTOIMMUNE RHEUMATIC DISEASES**

E. Pedretti, M.G. Lazzaroni, C. Nalli, L. Moschetti, A. Iodice, A. Lojacono, M. Motta, A. Molinaro, I. Cavazzana, F. Franceschini, P. Airò, J. Galli, L. Andreoli, E. Fazzi, A. Tincani  
(Brescia, Italy)

- PO4:20 THE IMPACT OF SYSTEMIC SCLEROSIS (SSC) ON WOMEN'S HEALTH EVALUATED WITH A NEW SSC-SPECIFIC PATIENT-REPORTED QUESTIONNAIRE**

L. Moschetti, E. Pedretti, F. Cucchi, A. Lojacono, F. Ramazzotto, C. Zanardini, S. Zatti, I. Cavazzana, F. Franceschini, P. Airò, L. Andreoli, A. Tincani, M.G. Lazzaroni  
(Brescia, Italy)

## POSTER SESSION 5: QUALITY OF LIFE (3)

Chair: C. Bouillot (Paris, France)

### PO5:21 LIFESTYLE IN ITALIAN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME: A PILOT STUDY

R. Izzo<sup>1</sup>, S. Colafrancesco<sup>1</sup>, A. Gattamelata<sup>1</sup>, A. Pinto<sup>1</sup>, L.M. Donini<sup>1</sup>, G. Guggino<sup>2</sup>, G. Grasso<sup>2</sup>, M. Matucci Cerinic<sup>3</sup>, M. Orlandi<sup>3</sup>, S. De Vita<sup>4</sup>, L. Quartuccio<sup>4</sup>, M. Binutti<sup>4</sup>, F. Conti<sup>1</sup>, R. Priori<sup>1</sup>  
(<sup>1</sup>Rome, Italy, <sup>2</sup>Palermo, Italy, <sup>3</sup>Florence, Italy, <sup>4</sup>Udine, Italy)

### PO5:22 ANALYSIS OF SEXUAL DYSFUNCTION IN WOMEN WITH SYSTEMIC SCLEROSIS COMPARED TO PRIMARY SJÖGREN SYNDROME USING THE ITALIAN VERSION OF QUALEX QUESTIONNAIRE

I. Bisconti, D. Mohammad Reza Beigi, G. Pellegrino, M. Cadar, F.R. Di Ciommo, F. Giardina, R. Priori,  
F. Conti, V. Riccieri  
(Rome, Italy)

### PO5:23 WHAT IMPACT DOES DISEASE ACTIVITY HAVE ON THE LIFE QUALITY OF SLE PATIENTS?

S. Salvucci, P. Fioretti, R. Santangeli, G. Montozzi, L. Gamba, C. Cocco, L. Manfredi, G. Moroncini  
(Ancona, Italy)

### PO5:24 THE EFFECTS OF LIFESTYLE INTERVENTIONS ON DISEASE ACTIVITY AND QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A SYSTEMATIC REVIEW

A.A. Sickinghe, B.C. Geertsema-Hoeve, S.J. van Schaik-Mast, J. Spierings, M. Limper  
(Utrecht, The Netherlands)

### PO5:25 CLINICAL FEATURES OF SYSTEMIC SCLEROSIS PATIENTS WITH IMPAIRED GASTROINTESTINAL QUALITY OF LIFE

I. Szabo, M. Muresan, M. Tamas, L. Muntean, S. Simon, I. Filipescu, C. Pamfil, R. Gutiu, D. Vaida-Voevod,  
S. Rednic  
(Cluj-Napoca, Romania)

## POSTER SESSION 6: QUALITY OF LIFE (4), INNOVATIVE APPROACH OF CLINICAL STUDIES

Chair: E. Hachulla (Lille, France)

### PO6:26 DAMAGE ACCRUAL IN MIXED CONNECTIVE TISSUE DISEASE

S. Ornowska, T. Gryn, J. Nalecz-janik, M. Wudarski, K. Swierkocka, K. Romanowska-Prochnicka, A. Matusiewicz, K. Bazala-beckowska, B. Stypinska, A. Paradowska-Gorycka, M. Olesinska (Warsaw, Poland)

### PO6:27 DAMAGE ACCRUAL IN IDIOPATHIC INFLAMMATORY MYOPATHIES: DATA FROM A MONOCENTRIC COHORT AND IMPACT ON PATIENTS' QUALITY OF LIFE

C. Cardelli<sup>1,2</sup>, S. Barsotti<sup>1,3</sup>, M. Diomedi<sup>1</sup>, F. Fattorini<sup>1</sup>, E. Laurino<sup>1</sup>, A. Tripoli<sup>1</sup>, L. Carli<sup>1</sup>, M. Mosca<sup>1</sup> (<sup>1</sup>Pisa, Italy, <sup>2</sup>Siena, Italy, <sup>3</sup>Livorno, Italy)

### PO6:28 GASTROINTESTINAL INVOLVEMENT IS ALREADY REPORTED IN AN ITALIAN VEDOSS COHORT: RESULTS FROM FROM A RHEUMATOLOGICAL NURSE ASSESSMENT

K. El Aoufy<sup>1</sup>, M.R. Melis<sup>1</sup>, G. Bandini<sup>1</sup>, G. Ghezzi<sup>1</sup>, E. Russo<sup>1</sup>, B.S. Fioretto<sup>1</sup>, E. Romano<sup>1</sup>, A. Amedei<sup>1</sup>, I. Rosa<sup>1</sup>, M. Manetti<sup>1</sup>, S. Guiducci<sup>1</sup>, A. Moggi-Pignone<sup>1</sup>, M. Matucci Cerinic<sup>1,2</sup>, L. Rasero<sup>1</sup>, Y. Longobucco<sup>1</sup>, S. Bellando Randone<sup>1</sup> (<sup>1</sup>Florence, Italy, <sup>2</sup>Milan, Italy)

### PO6:29 NAILFOLD CAPILLAROSCOPY AND CANDIDATE BIOMARKER LEVELS IN SYSTEMIC SCLEROSIS - ASSOCIATED PULMONARY HYPERTENSION; A CROSS SECTIONAL STUDY

J. Lemmers<sup>1</sup>, A.P.M. van Caam<sup>1</sup>, B. Kersten<sup>1</sup>, C.H.M. van den Ende<sup>1</sup>, H. Knaapen<sup>1</sup>, A.P.J. van Dijk<sup>1</sup>, W. Hagemolen of ten Have<sup>1</sup>, F.H.J. van den Hoogen<sup>1</sup>, H. Koenen<sup>1</sup>, S. van Leuven<sup>1</sup>, W. Alkema<sup>2</sup>, R. Smeets<sup>1</sup>, M.C. Vonk<sup>1</sup> (<sup>1</sup>Nijmegen, The Netherlands, <sup>2</sup>Groningen, The Netherlands)

### PO6:30 NETOSIS IN ANTIPHOSPHOLIPID SYNDROME

S. Mancuso<sup>1</sup>, C. Giacomassi<sup>2</sup>, S. Truglia<sup>1</sup>, E. Corsiero<sup>2</sup>, M. Caliste<sup>2</sup>, C. Barbatì<sup>1</sup>, C. Alessandri<sup>1</sup>, M. Lewis<sup>2</sup>, M. Bombardieri<sup>2</sup>, F. Conti<sup>1</sup> (<sup>1</sup>Rome, Italy, <sup>2</sup>London, United Kingdom)



**Friday, 21<sup>st</sup> April 2023**  
**10:20 - 11:40**

### **POSTER SESSION 7: DIAGNOSIS & CLINICAL MANAGEMENT (1)**

Chair: L. Arnaud (Strasbourg, France)

**PO7:31 ANTIPHOSPHOLIPID SYNDROME AND TYPE I INTERFERON SIGNATURE: A CLUSTER AND CORRESPONDENCE ANALYSIS APPROACH**

I. Cecchi<sup>1</sup>, M. Radin<sup>1</sup>, A. Barinotti<sup>1</sup>, S.G. Foddai<sup>1</sup>, E. Rubini<sup>1</sup>, A. Suarez<sup>2</sup>, J. Rodriguez-Carrio<sup>2</sup>, S. Sciascia<sup>1</sup>, D. Roccatello<sup>1</sup>  
(<sup>1</sup>Turin, Italy, <sup>2</sup>Oviedo, Spain)

**PO7:32 LONG-TERM CLINICAL OUTCOMES OF PATIENTS WITH LUPUS NEPHRITIS TREATED WITH AN INTENSIFIED B-CELL DEPLETION PROTOCOL WITHOUT MAINTENANCE THERAPY: A PROSPECTIVE STUDY**

D. Roccatello, S. Sciascia, C. Naretto, M. Alpa, R. Fenoglio, M. Ferro, G. Quattrocchio, E. Rubini, E. Rahbani, V. Modena, D. Rossi  
(Turin, Italy)

**PO7:33 QRISK VS AGAPSS: CARDIOVASCULAR RISK ASSESSMENT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

A. Barinotti, M. Radin, I. Cecchi, S.G. Foddai, E. Rubini, E. Menegatti, S. Sciascia, D. Roccatello  
(Turin, Italy)

**PO7:34 CLINICAL-PATHOLOGICAL CHARACTERISTICS OF RENAL INJURIES IDENTIFY DIFFERENT CLUSTERS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES: A MULTICENTER STUDY**

S. Sciascia<sup>1</sup>, J. Yazdany<sup>2</sup>, S.V. Seshan<sup>3</sup>, J.U. Becker<sup>4</sup>, G. Moroni<sup>5</sup>, D. Andrade<sup>6</sup>, G. Emmi<sup>7</sup>, M.J. Cuadrado<sup>1</sup>, M. Radin<sup>1</sup>, I. Cecchi<sup>1</sup>, E. De Simone<sup>1</sup>, A. Barreca<sup>1</sup>, L. Caroti<sup>7</sup>, S. Innocenti<sup>7</sup>, A. Barinotti<sup>1</sup>, R. Fenoglio<sup>1</sup>, D. Roccatello<sup>1</sup>  
(<sup>1</sup>Turin, Italy, <sup>2</sup>San Francisco, USA, <sup>3</sup>New York, USA, <sup>4</sup>Cologne, Germany, <sup>5</sup>Rozzano, Italy, <sup>6</sup>Sao Paolo, Brazil, <sup>7</sup>Florence, Italy)

**PO7:35 A STEP FORWARD IN EARLY RECOGNITION OF SYSTEMIC SCLEROSIS: DATA FROM THE LEIDEN CCISS COHORT**

S. Liem<sup>1</sup>, J. Ciaffì<sup>1,2</sup>, S. Ahmed<sup>1</sup>, L. Beaart-van de Voorde<sup>1</sup>, A. Schouffoer<sup>1,3</sup>, J. Geelhoed<sup>1</sup>, N. Ajmone Marsan<sup>1</sup>, T. Huizinga<sup>1</sup>, J. de Vries-Bouwstra<sup>1</sup>  
(<sup>1</sup>Leiden, The Netherlands, <sup>2</sup>Bologna, Italy, <sup>3</sup>The Hague, The Netherlands)

**PO7:36 PREDICTORS OF INTERSTITIAL LUNG INVOLVEMENT IN SYSTEMIC SCLEROSIS**

C. Sieiro Santos, R. Rego Salgueiro, C. Moriano Morales, C. Álvarez Castro, E. Díez Álvarez  
(León, Spain)

**PO7:37 SUCCESSFUL USE OF MONOCLONAL AND ANTIVIRAL THERAPY IN IMMUNOCOMPROMISED PATIENTS WITH PERSISTENT AND/OR RELAPSING COVID-19**

L. Gori, M. Spinicci, L. Graziani, F. Lavorini, E. Cavigli, E. Rosi, A. Bartoloni, P. Parronchi, V. Luzzi, C. Comin, L. Ciani, S. Tomassetti  
(Florence, Italy)

**PO7:38 AN ATYPICAL AND SEVERE GASTROINTESTINAL INVOLVEMENT IN A RARE SYSTEMIC AUTOIMMUNE DISEASE-HOW AGE AND TRIGGER FACTORS MAY IMPACT ON THE CLINICAL PICTURE**

C. Cigolini, E. Elefante, C. Tani, F. Ferro, L. Carli, M. Mosca  
(Pisa, Italy)

**PO7:39 CLINICAL, HISTOLOGIC AND PROGNOSTIC CHARACTERISTICS OF CLINICALLY AMYOPATHIC DERMATOMYOSITIS**

M. Fornaro, F. Cacciapaglia, F. Girolamo, M. Ruggieri, M. Mastrapasqua, C. Capuano, L. Coladonato, D. D'Abbicco, F. Iannone  
(Bari, Italy)

**PO7:40 OBSTETRIC MORBIDITY IN WOMEN WITH ANTI-PHOSPHOLIPID-LIKE SYNDROME—PREVENTABLE OR NOT?**

C. Moura, I. Gil, I. Castro, A. Braga, J. Braga  
(Porto, Portugal)

**PO7:41 PTX3 AS A NEW BIOMARKER OF DISEASE ACTIVITY IN IDIOPATHIC INFLAMMATORY MYOPATHIES**

M. Fornaro<sup>1</sup>, F. Girolamo<sup>1</sup>, F. Cacciapaglia<sup>1</sup>, G. Carabellose<sup>2</sup>, R. Bizzoca<sup>1</sup>, C. Scioscia<sup>1</sup>, L. Coladonato<sup>1</sup>, G. Lopalco<sup>1</sup>, M. Ruggieri<sup>1</sup>, M. Mastrapasqua<sup>1</sup>, D. D'Abbicco<sup>1</sup>, F. Iannone<sup>1</sup>  
(<sup>1</sup>Bari, Italy, <sup>2</sup>Foggia, Italy)

**PO7:42 INTERFERENCE IN POINT-OF-CARE INTERNATIONAL NORMALIZED RATIO MONITORING IN PATIENTS WITH LUPUS ANTICOAGULANT IS CORRELATED WITH ANTI-B2-GLYCOPROTEIN I ANTIBODY TITERS**

M.L. Limper, T. Noordermeer, C. Wong, J. Jansma, N. Wiersma, M. Zivkovic, A. Huisman, R. Urbanus  
(Utrecht, The Netherlands)

**PO7:43 PEDIATRIC MIXED CONNECTIVE TISSUE DISEASE (PMCTD) ONSET: A SYSTEMATIC REVIEW**

A. Terminiello, E. Marrani, I. Pagnini, I. Maccora, M.V. Mastrolia, G. Simonini  
(Florence, Italy)

**POSTER SESSION 8: DIAGNOSIS & CLINICAL MANAGEMENT (2)**

Chair: T. Alexander (Berlin, Germany)

**PO8:44 A LIFE JOURNEY WITH SCLERODERMA**

G. Strugariu, C. Pomirleanu, L.M. Grecu, C. Ancuta  
(Iasi, Romania)

**PO8:45 CLINICAL PROFILE OF PATIENTS WITH SJÖGREN'S SYNDROME HOSPITALIZED: IMPROVING PHENOTYPIC STRATIFICATION TO SUCCEED AT VALUE-BASED CARE**

I.C. Navarro Garcia, E. Gianni, S. Fonzetti, G. La Rocca, G. Fulvio, V. Signorini, F. Ferro, M. Mosca, C. Baldini  
(Pisa, Italy)

**PO8:46 PATIENT-REPORTED OUTCOMES TO ASSESS DYSPNEA IN INTERSTITIAL LUNG DISEASE AND PULMONARY HYPERTENSION, A SYSTEMATIC LITERATURE REVIEW OF MEASUREMENT PROPERTIES**

J. Lemmers, M.C. Vonk, C.H.M. van den Ende  
(Nijmegen, The Netherlands)

**PO8:47 REAL-WORLD EXPERIENCE FROM A COHORT OF SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION**

M. Fornaro, E. Adesso, S. Stano, L. De Michele, E. De Tommasi, N. Camassa, C. D'Agostino, F. Iannone,  
F. Cacciapaglia  
(Bari, Italy)

**PO8:48 FREE-BETAHCG AND PAPP-A IN PREGNANT PATIENTS WITH CONNECTIVE TISSUE DISEASES AND/OR ANTIPHOSPHOLIPID AUTOANTIBODIES: RESULTS FROM A MONOCENTRIC COHORT**

D. Zucchi, C. Tani, F. Monacci, C. Ietto, E. Elefante, S. Gori, V. Gelsi, L. Carli, F.A.L. Strigini, M. Mosca  
(Pisa, Italy)

**PO8:49 LONG-TERM OUTCOMES FROM A LARGE COHORT OF IGG4-RELATED AUTOIMMUNE PANCREATITIS PATIENTS**

M. Lanzillotta, J. Mahajane, V. Batani, L. Dagna, E. Della Torre  
(Milan, Italy)

**PO8:50 IGG4-RELATED-AUTOIMMUNE PANCREATITIS IN EUROPE: CLINICAL PROFILE AND RESPONSE TO TREATMENT**

M. Lanzillotta<sup>1</sup>, K. Overbeek<sup>2</sup>, P. Macinga<sup>3</sup>, J. Paulsen<sup>4</sup>, M. Lohr<sup>5</sup>, E. Della Torre<sup>1</sup>

(<sup>1</sup>Milan, Italy, <sup>2</sup>Rotterdam, The Netherlands, <sup>3</sup>Prague, Czech Republic, <sup>4</sup>Aalborg, Denmark, <sup>5</sup>Stockholm, Sweden)

**PO8:51 WOUND-CARE NURSING AS A FUNDAMENTAL ACTOR IN THE MANAGEMENT OF SYSTEMIC SCLEROSIS-RELATED DIGITAL ULCERS**

V. Venturini, M. Di Battista, M. Da Rio, C. Puccini, A. Della Rossa, M. Mosca  
(Pisa, Italy)

**PO8:52 SARCOPENIA IN MYOSITIS PATIENTS: A MARKER OF MUSCLE DAMAGE ASSOCIATED WITH MYOSITIS SEVERITY AND DISABILITY**

M. Giannini, L. Debrut, A.L. Charles, J. Blaess, R.M. Javier, A. Charloux, B. Geny, A. Meyer  
(Strasbourg, France)

**PO8:53 IGG4-RELATED DISEASE PRESENTING AS AN OBSTRUCTIVE ACUTE RENAL FAILURE: A CASE REPORT**

C. Castellani, C. Gioia, C. Alessandri, R. Priori, F. Conti, R. Scrivo  
(Rome, Italy)

**PO8:54 A 72-YEAR-OLD MAN WITH ANAEMIA, FEVER, CHONDROITIS AND A HISTORY OF THROMBOSIS. A CASE REPORT OF VEXAS SYNDROME.**

L. Matromanno, L. Di Sanzo, M. Favretti, F. Giardina, R. Scrivo, F. Conti, R. Priori, C. Alessandri  
(Rome, Italy)

**PO8:55 SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASES IN THE COVID-19 ERA: THE ROLE OF THE MULTIDISCIPLINARY APPROACH**

G. Pellegrino, D. Mohammad Reza Beigi, N. Landini, S. Truglia, I. Bisconti, M. Cadar, F.R. Di Ciommo,  
K. Stefanantoni, V. Panebianco, F. Conti, V. Riccieri  
(Rome, Italy)

**PO8:56 MILWAUKEE SHOULDER SYNDROME: A CASE REPORT OF UNRECOGNIZED DISEASE IN AN ELDERLY WOMAN**

L. Di Sanzo, L. Mastromanno, M. Favretti, C. Castellani, C. Alessandri, R. Scrivo, F. Conti  
(Rome, Italy)

## POSTER SESSION 9: DIAGNOSIS & CLINICAL MANAGEMENT (3)

Chair: TBD

**PO9:57 DESCRIPTIVE ANALYSIS OF AN UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE (UCTD) MONOCENTRIC COHORT OF PATIENTS FOLLOWED UP IN THE THIRD LEVEL RHEUMATOLOGY CENTER OF BRESCIA.**

S. Piantoni, A. Caproli, E. Kessler, A. Tincani, F. Franceschini, I. Cavazzana  
(Brescia, Italy)

**PO9:58 ROS-INDUCED FIBRINOGEN ALTERATIONS AND ATHEROTHROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS**

G. Emmi<sup>1</sup>, M. Becatti<sup>1</sup>, A. Bettoli<sup>1</sup>, A. Mannucci<sup>1</sup>, F.R. Argento<sup>1</sup>, E. Fini<sup>1</sup>, M. Nicastro<sup>2</sup>, I. Mattioli<sup>1</sup>, E. Silvestri<sup>1</sup>, N. Taddei<sup>1</sup>, A. Vaglio<sup>1</sup>, C. Fiorillo<sup>1</sup>, D. Prisco<sup>1</sup>  
(<sup>1</sup>Firenze, Italy, <sup>2</sup>Parma, Italy)

**PO9:59 HUGHES-STOVIN SYNDROME: A DIAGNOSTIC AND THERAPEUTIC CHALLENGE**

F. Cirilli, R. Bertola, A. Lo Monaco, M. Govoni  
(Ferrara, Italy)

**PO9:60 OPTIMISE - VALIDATION OF THE SLEDAI-P SELF-QUESTIONNAIRE, COMPLETED BY THE PATIENT, TO MEASURE THE ACTIVITY OF THE SYSTEMIC LUPUS**

N. Zein<sup>1</sup>, M. Scherlinger<sup>2</sup>, J.F. Kleinmann<sup>2</sup>, A. Folliasson<sup>3</sup>, J. Sibilia<sup>2</sup>, M. Riviere<sup>1</sup>, Z. Amoura<sup>3</sup>  
(<sup>1</sup>Metz, France, <sup>2</sup>Strasbourg, France, <sup>3</sup>Paris, France)

**PO9:61 INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS PATIENTS: ROLE OF LUNG ULTRASOUND CHANGES COMPARED WITH QUANTITATIVE COMPUTED TOMOGRAPHY VIA AUTOMATED TEXTURE ANALYSIS SOFTWARE**

D. Mohammad Reza Beigi<sup>1</sup>, G. Pellegrino<sup>1</sup>, M. Loconte<sup>1</sup>, N. Landini<sup>2</sup>, M. Mattone<sup>2</sup>, G. Paone<sup>3</sup>, S. Truglia<sup>1</sup>, F.R. Di Ciommo<sup>1</sup>, I. Bisconti<sup>1</sup>, M. Cadar<sup>1</sup>, K. Stefanantoni<sup>1</sup>, V. Panebianco<sup>2</sup>, F. Conti<sup>1</sup>, V. Riccieri<sup>1</sup>  
(Rome, Italy)

**PO9:62 EARLY SYSTEMIC LUPUS ERYTHEMATOSUS OR KIKUCHI-FUJIMOTO DISEASE?**

S. Salvucci<sup>1</sup>, L. Biondi<sup>2</sup>, P. Barbatelli<sup>2</sup>, P.M. Squadroni<sup>2</sup>, F. Giorgetti<sup>2</sup>, M. Gaetani<sup>2</sup>, D. Menghini<sup>2</sup>, M.L. Minnucci<sup>2</sup>, G. Moroncini<sup>1</sup>  
(<sup>1</sup>Ancona, Italy, <sup>2</sup>Civitanova Marche, Italy)

**PO9:63 IDENTIFICATION OF NEW TELOMERE - AND TELOMERASE-ASSOCIATED AUTOANTIGENS IN SYSTEMIC SCLEROSIS**

J. Vulsteke<sup>1</sup>, Y. Piette<sup>2</sup>, C. Bonroy<sup>2</sup>, D. Blockmans<sup>1</sup>, P. De Haes<sup>1</sup>, S. Vanderschueren<sup>1</sup>, P. Verschueren<sup>1</sup>, K. G. Claeys<sup>1</sup>, J. L. Lenaerts<sup>1</sup>, W. A. Wuyts<sup>1</sup>, V. Smith<sup>2</sup>, E. De Langhe<sup>1</sup>, X. Bossuyt<sup>1</sup>  
(<sup>1</sup>Leuven, Belgium, <sup>2</sup>Ghent, Belgium)

**PO9:64 THE ROLE OF GENDER AND OVERLAP AUTOIMMUNITY IN SYSTEMIC SCLEROSIS: EXPERIENCE FROM A TERTIARY CARE CENTER FROM NORTHERN ITALY**

G. Amati, A. Spinella, G. Sandri, A. Melegari, M. De Pinto, S. Rondinone, M.T. Mascia, D. Giuggioli  
(Modena, Italy)

**PO9:65 A CASE OF MYOCARDITIS IN A PATIENT WITH BEHCET'S SYNDROME**

E. Balbinot, F. Ucci, G. Tripodi, C. Ciancarella, A.I. Celia, R. Scrivo, C. Alessandri, F. Conti  
(Rome, Italy)

**PO9:66 THE AUTOIMMUNE RESEARCH AND COLLABORATION HUB (ARCH) IN THE NETHERLANDS: AIMING TO IMPROVE HEALTHCARE FOR ALL PATIENTS WITH RARE, SYSTEMIC AUTOIMMUNE DISEASES**

J. De Vries-Bouwstra<sup>1,2</sup>, F. Bonte-Mineur<sup>2,3</sup>, E. Brouwer<sup>2,4</sup>, R.J. Goekoop<sup>2,5</sup>, C.L. Overman<sup>2</sup>, Z. Brkic<sup>3</sup>, M. Limper<sup>2</sup>, M.C. Vonk<sup>6</sup>, J. Nabuurs · J.L.L. Scheerhoorn-Pullen<sup>2</sup>, A.E. Voskuyl<sup>7</sup>, Y.K.O. Teng<sup>1,2</sup>, A.R.C.H. Study group<sup>2</sup>  
(<sup>1</sup>Leiden, The Netherlands, <sup>2</sup>Utrecht, The Netherlands, <sup>3</sup>Rotterdam, The Netherlands, <sup>4</sup>Groningen, The Netherlands, <sup>5</sup>Den Haag, The Netherlands, <sup>6</sup>Nijmegen, The Netherlands, <sup>7</sup>Amsterdam, The Netherlands)

**PO9:67 RARE PULMONARY MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): DESCRIPTION OF SYMPTOMATIC NON-SEROSITIC LUNG INVOLVEMENT IN A MONOCENTRIC COHORT**

D. Schilirò, E. Elefante, C. Stagnaro, V. Signorini, D. Zucchi, F. Trentin, G. La rocca, L. Carli, F. Ferro, C. Tani, M. Mosca  
(Pisa, Italy)

**PO9:68 RITUXIMAB AS ADJUNCTIVE THERAPY FOR CHILDHOOD-ONSET IMMUNE-MEDIATED NECROTIZING MYOPATHY**

E. Marrani, S. Abu Rumeileh, I. Bertacca, M.V. Mastrolia, I. Maccora, I. Pagnini, G. Simonini  
(Florence, Italy)

**PO9:69 ULTRA-HIGH FREQUENCY ULTRASONOGRAPHY OF LABIAL GLANDS IN PEDIATRIC SJÖGREN'S SYNDROME: A PRELIMINARY STUDY**

E. Marrani<sup>1</sup>, C. Virgili<sup>1</sup>, G. Fulvio<sup>2</sup>, R. Izzetti<sup>2</sup>, V. Dini<sup>2</sup>, T. Oranges<sup>1</sup>, C. Baldini<sup>2</sup>, G. Simonini<sup>1</sup>  
(<sup>1</sup>Florence, Italy, <sup>2</sup>Pisa, Italy)

**POSTER SESSION 10: DIAGNOSIS & CLINICAL MANAGEMENT (4)**

Chair: R. Cervera (Barcelona, Spain)

**PO10:70 NEUROLOGICAL INVOLVEMENT IN A MONOCENTRIC COHORT OF PATIENTS WITH SERONEGATIVE ANTIPHOSPHOLIPID SYNDROME**

L. Rapino, S. Truglia, S. Mancuso, M. De Michele, D. Toni, I. Berto, M. Sorice, R. Misasi, A. Capozzi, C. Alessandri, F. Conti  
(Rome, Italy)

**PO10:71 A CAUTIONARY TALE ABOUT THE CONSEQUENCES OF OVERLOOKING CLINICAL MANIFESTATIONS POTENTIALLY LINKED TO RARE DISEASES: A CASE REPORT ON A LATE DIAGNOSIS OF BIRT-HOGG-DUBÉ SYNDROME**

G. Acquati<sup>1</sup>, F. Inglese<sup>2</sup>, S. Tomassetti<sup>1</sup>, E. Rosi<sup>1</sup>  
(<sup>1</sup>Florence, Italy, <sup>2</sup>Pistoia, Italy)

**PO10:72 EXTRACELLULAR VESICLES AS A NOVEL BIOMARKERS OF EARLY DISEASE STAGE IN SYSTEMIC SCLEROSIS**

J.C. Colic<sup>1</sup>, I.P. Pruner<sup>2</sup>, N.D. Damjanov<sup>1</sup>, J.A. Antovic<sup>2</sup>, M.S. Sefik-Bukilica<sup>1</sup>, A.A. Antovic<sup>2</sup>  
(<sup>1</sup>Belgrade, Serbia, <sup>2</sup>Stockholm, Sweden)

**PO10:73 COMMERCIAL PROTHROMBIN ANTIGEN VARIABILITY IN ANTIPHOSPHOLIPID ANTIBODIES TESTING**

A. Barinotti<sup>1</sup>, I. Gonzalez<sup>2</sup>, L. Martinez<sup>2</sup>, M. Radin<sup>1</sup>, I. Cecchi<sup>1</sup>, C. Garcia<sup>2</sup>, J. Hervas<sup>2</sup>, S.G. Foddai<sup>1</sup>, P. Lopez<sup>2</sup>, D. Roccatello<sup>1</sup>, A. Krimmer<sup>2</sup>, D. Lucia<sup>2</sup>, M. Mahler<sup>2</sup>, S. Sciascia<sup>1</sup>  
(<sup>1</sup>Turin, Italy, <sup>2</sup>Barcelona, Spain)

**PO10:74 ERASMUS SYNDROME: SCLERODERMA RENAL CRISIS SINE SCLERODERMA?**

C. Gioia, R. Izzo, D. Accapezzato, E. Rossi, P. Pignatelli  
(Rome, Italy)

**PO10:75 HISTOPATHOLOGY FINDINGS IN FIRST TIME RENAL BIOPSY IN SUSPICION OF LUPUS NEPHRITIS - WHAT DO WE FIND?**

F. Faustini, L. Karlsson, A. Zickert, E. Svenungsson, J. Schmidt-Mende, I. Gunnarsson  
(Stockholm, Sweden)

**PO10:76 LIKE FATHER, LIKE SON: WHEN LUPUS IS MALE**

F. Fattorini, A. Valevich, M. Diomedi, E. Elefante, R. Talarico, M. Mazzantini, C. Baldini, C. Tani, M. Mosca  
(Pisa, Italy)

**PO10:77 RESPIRATORY INVOLVEMENT IN PEDIATRIC IDIOPATHIC INFLAMMATORY MYOPATHIES: A SYSTEMATIC REVIEW**

E. Marrani, S. Abu Rumeileh, V. Maniscalco, M.V. Mastrolia, I. Maccora, I. Pagnini, G. Simonini  
(Florence, Italy)

**PO10:78 ABRUPT CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN ERDHEIM-CHESTER DISEASE: CLINICAL EXPRESSION, MANAGEMENT, AND OUTCOME OF TWO CASES**

D. Schilirò, D. Zucchi, M. Di Battista, N. Italiano, G. Casciarano, E. Elefante, F. Ferro, R. Talarico, M. Mosca  
(Pisa, Italy)

**PO10:79 ACTIVITY AND REMISSION IN SYSTEMIC LUPUS ERYTHEMATOSUS – TRANSVERSAL ANALYSIS OF A TERTIARY CENTER IN PORTUGAL**

A. Lamas<sup>1</sup>, J. Morais<sup>1,2</sup>, I. Ostapiuk<sup>1,3</sup>, F. Farinha<sup>1</sup>, A. Marinho<sup>1</sup>, R. Faria<sup>1</sup>, C. Vasconcelos<sup>1</sup>  
(<sup>1</sup>Porto, Portugal, <sup>2</sup>Matosinhos, Portugal, <sup>3</sup>Guarda, Portugal)

**PO10:80 SJÖGREN'S SYNDROME: IDENTIFICATION OF PREDICTORS OF DISEASE SEVERITY**

C. Cardamone, G. Ciannarella, I. Carrieri, P. Vitale, A. Sottolano, R. Parente, M. Triggiani  
(Salerno, Italy)

**PO10:81 TRIGGER FACTORS IN RELAPSING POLYCHONDRITIS: A PILOT QUESTIONNAIRE STUDY AND A LITERATURE REVIEW**

C. Bucsa, A. Tarnovan-Cozma, C. Pamfil, M.M. Tamas, I. Filipescu, I. Felea, L. Muntean, S. Simon, L. Ghib,  
S. Rednic, L. Damian  
(Cluj-Napoca, Romania)

**PO10:82 THE IMPACT OF CARDIOPULMONARY INVOLVEMENT ON THE SIX-MINUTE WALK TEST IN PATIENTS WITH SYSTEMIC SCLEROSIS**

S. Ahmed, S. Liem, T.W.J. Huizinga, J.K. de Vries-Bouwstra  
(Leiden, The Netherlands)

## POSTER SESSION 11: DIAGNOSIS & CLINICAL MANAGEMENT (5)

Chair: TBD

### PO11:83 RHEUMATOID ARTHRITIS IN HYPERMOBILE EHLERS-DANLOS SYNDROME

A. Cozma, A. Vasiliu, A.D. Bilous, C. Pamfil, I. Filipescu, I. Felea, M.M. Tamas, L. Muntean, S. Simon, S. Rednic, L. Damian  
(Cluj-Napoca, Romania)

### PO11:84 ANTI MDA5 DERMATOMYOSITIS: NOT ONLY PERIPHERAL VASCULAR AND LUNG INVOLVEMENT

M. Diomedi, C. Cardelli, E. Laurino, F. Fattorini, S. Barsotti, A. Tripoli, L. Carli, M. Mosca  
(Pisa, Italy)

### PO11:85 EXTENSIVE CALCINOSIS AS THE MAIN ONSET MANIFESTATION IN ADULTS ONSET DERMATOMYOSITIS

I. Filipescu, L. Damian, I. Felea, C. Pamfil, D. Moldovan, L. Muntean, S. Redniic  
(Cluj-Napoca, Romania)

### PO11:86 CLINICAL PROFILE OF ANTISYNTHETASE SYNDROME IN A ROMANIAN TERTIARY CENTER – CASE SERIES

D.A.M. Vaida-Voevod, C.M. Neag, L.O. Damian, I.E. Szab, R.I. Rosca, M.M. Tamas, I. Felea, I. Filipescu, C. Pamfil, S.P. Simon, L.M. Muntean, S. Rednic  
(Cluj-Napoca, Romania)

### PO11:87 IGG4-RELATED PROSTATITIS: A SYSTEMATIC LITERATURE REVIEW

V. Surdu, L. Damian, I. Felea, D. Crisan, N. Crisan, T. Onea, B. Stancu, S. Rednic, C. Pamfil  
(Cluj-Napoca, Romania)

### PO11:88 RELAPSING POLYCHONDRTIS' SINGLE CENTER COHORT DESCRIPTION: CLINICAL MANIFESTATIONS AND INFLAMMATORY AND HAEMATOLOGICAL COMORBIDITIES

A. Lamas, D.G. Oliveira, T. Mendonça, F. Farinha, R. Faria, C. Vasconcelos  
(Porto, Portugal)

**PO11:89 THE IMPORTANCE OF DIAGNOSIS IN INTESTINAL LUNG DISEASE. A CASE REPORT.**

E. Mazzarella, G. Acquati, S. Tomassetti, F. Lavorini  
(Florence, Italy)

**PO11:90 RISK FACTORS FOR RECURRENT THROMBOSIS AND CAUSE OF DEATH IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME; A SWEDISH COHORT STUDY**

A. Antovic, N. Karandyszowska, M. Magnusson, E. Svenungsson, M. Bruzelius  
(Stockholm, Sweden)

**PO11:91 A CASE OF PEDIATRIC ANTIPHOSPHOLIPID SYNDROME WITH SUBSEQUENT DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS FOLLOWING COVID-19**

G. Sciarra, E. Molteni, L. Di Sanzo, C. Castellani, G. Bevignani, F. Conti, R. Scrivo  
(Rome, Italy)

**PO11:92 A CASE OF PURULENT GONOCOCCAL ARTHRITIS IN A PATIENT SUFFERING FROM GOUT**

G. Sciarra, E. Molteni, L. Di Sanzo, C. Castellani, G. Bevignani, C. Alessandri, F. Conti, R. Scrivo  
(Rome, Italy)

**PO11:93 EMERGENCY IN RARE RHEUMATOLOGIC DISEASES: DATA FROM A SINGLE-CENTER EXPERIENCE**

P. Triggianese, A. D'Antonio, I. Cristiano, C. Minerba, A. Bergamini, M.S. Chimenti  
(Rome, Italy)

**PO11:94 APS AND PREGNANCY: IMPORTANCE OF PRECONCEPTION APPOINTMENTS, A RETROSPECTIVE STUDY**

S. Aleixo<sup>1,2</sup>, G. Carvalheiras<sup>1</sup>, C. Vasconcelos<sup>1</sup>, F. Farinha<sup>1</sup>  
(<sup>1</sup>Porto, Portugal, <sup>2</sup>Faro, Portugal)

**PO11:95 IGG4 RELATED FIBROSIS - A RED FLAG IN CANCER DIAGNOSIS?**

G. Fabozzi, C. Cardamone, C. Ciampa, M. Triggiani  
(Salerno, Italy)

## POSTER SESSION 12: COMORBIDITIES, THERAPEUTIC MANAGEMENT (1)P

Chair: J.M. Van Laar (Utrecht, The Netherlands)

### PO12:96 ARE GASTROINTESTINAL MANIFESTATIONS AND NUTRITIONAL STATUS CORRELATED IN SYSTEMIC SCLEROSIS? A SINGLE-CENTER EXPERIENCE DRIVEN BY BIOELECTRICAL IMPEDANCE VECTOR ANALYSIS.

G. De Mattia, M. Di Battista, M. Da Rio, A. Rossi, A. Della Rossa, M. Mosca  
(Pisa, Italy)

### PO12:97 SYSTEMIC LUPUS ERYTHEMATOSUS AND OSTEOPOROSIS: EVALUATION OF PREVALENCE, BONE FRACTURE RISK AND THERAPEUTICAL APPROACHES. EXPERIENCE OF A MONOCENTRIC COHORT.

P. Semeraro, M. Salvi, C. Orlandi, I. Cavazzana, M. Fredi, A. Tincani, F. Franceschini  
(Brescia, Italy)

### PO12:98 AUTOIMMUNE COMORBIDITIES IN CONNECTIVE TISSUE DISEASES: POSSIBLE ASSOCIATION WITH AUTOANTIBODIES PATTERNS AND HEMATOLOGICAL MALIGNANCIES

A. Corrado, S. Stefania, V. Rella, A. Altomare, F.P. Cantatore, C. Rotondo  
(Foggia, Italy)

### PO12:99 CHARACTERISTICS AND INCIDENCE OF SARS-COV-2 INFECTION IN AN ITALIAN COHORT OF PATIENTS WITH IGG4 RELATED DISEASE

L. Matromanno<sup>1</sup>, A. Gattamelata<sup>1</sup>, S. Colafrancesco<sup>1</sup>, S. Truglia<sup>1</sup>, F. Giardina<sup>1</sup>, E. Simoncelli<sup>1</sup>, M. Villa<sup>1</sup>,  
B. Lucchino<sup>2</sup>, F. Conti<sup>1</sup>, R. Priori<sup>1</sup>  
(<sup>1</sup>Rome, Italy, <sup>2</sup>Verona, Italy)

### PO12:100 COMORBIDITIES IN PATIENTS WITH SYSTEMIC SCLEROSIS: TO IDENTIFY PATIENTS' SUBTYPES ACCORDING TO LUNG AND CARDIOVASCULAR INVOLVEMENT

P. Triggianese, E. Greco, B. Kroegler, A. Vendola, S. Modica, P. Conigliaro, A. Bergamini, M.S. Chimenti  
(Rome, Italy)

**PO12:101 BODY COMPOSITION AND MALNUTRITION - A PILOT STUDY ON SYSTEMIC SCLEROSIS**

R. Rosca, I.E. Szabo, I. Cozma, A.D. Bilous, A. Marian, G.A. Stoica, D.A.M. Vaida-Voevod, C. Pamfil, L.M. Muntean, L.O. Damian, I. Felea, M.M. Tamas, I. Filipescu, S.P. Simon, D. Fodor, S. Rednic (Cluj-Napoca, Romania)

**PO12:102 CLINICAL DELPHI ON APL NEGATIVIZATION: REPORT FROM THE ITALIAN SOCIETY OF RHEUMATOLOGY WORKING GROUP ON ANTIPHOSPHOLIPID SYNDROME**

S.G. Foddai<sup>1</sup>, S. Sciascia<sup>1</sup>, A. Barinotti<sup>1</sup>, I. Cecchi<sup>1</sup>, M. Radin<sup>1</sup>, E. Rubini<sup>1</sup>, D. Roccatello<sup>1</sup>, S. SIR-APS<sup>2</sup>, A. Tincani<sup>3</sup> (Turin, Italy, <sup>2</sup>Milan, Italy, <sup>3</sup>Brescia, Italy)

**PO12:103 NIPOCALIMAB MECHANISM OF ACTION, SAFETY, AND TOLERABILITY**

T. Ebrahim<sup>1</sup>, A. Pierce<sup>1</sup>, J. Leu<sup>2</sup>, W. Noël<sup>3</sup>, A. Vermeulen<sup>4</sup>, L. Ling<sup>1</sup>  
(<sup>1</sup>Cambridge, USA, <sup>2</sup>Spring House, USA, <sup>3</sup>Flemish Brabant, Belgium, <sup>4</sup>Beerse, Belgium)

**PO12:104 NIPOCALIMAB'S SELECTIVE TARGETING OF FCRN AND IGG CLEARANCE PRESERVES KEY IMMUNE FUNCTIONS**

L. Ling<sup>1</sup>, S. Tyler<sup>1</sup>, C. Beneduce<sup>1</sup>, F. Yu<sup>1</sup>, J. Brown<sup>1</sup>, W. Noël<sup>2</sup>, S. Kumar<sup>1</sup>, R. Xu<sup>1</sup>, J. Duffner<sup>1</sup>, W. Avery<sup>3</sup>  
(<sup>1</sup>Cambridge, USA, <sup>2</sup>Flemish Brabant, Belgium, <sup>3</sup>Watertown, USA)

**PO12:105 ANTI-THYMOCYTE GLOBULIN EXPOSURE IN TREATMENT RESPONSE OF PATIENTS WITH SYSTEMIC SCLEROSIS UNDERGOING AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION**

Y. Chiu, A. Drijver, R. Admiraal, A. van Rhenen, S. Nierkens, J. van Laar, J. Spierings (Utrecht, The Netherlands)

**PO12:106 DESIGN OF A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF NIPOCALIMAB IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES**

C. Najem<sup>1</sup>, J. Craig<sup>1</sup>, L. Christopher-Stine<sup>2</sup>, F. Zazzetti<sup>3</sup>, W. Noël<sup>4</sup>, C. Blango Sr.<sup>1</sup>, C. Karyekar<sup>1</sup>, R. Aggarwal<sup>5</sup>  
(<sup>1</sup>Spring House, USA, <sup>2</sup>Maryland, USA, <sup>3</sup>Buenos Aires, Argentina, <sup>4</sup>Flemish Brabant, Belgium, <sup>5</sup>Pennsylvania, USA)

### POSTER SESSION 13: THERAPEUTIC MANAGEMENT (2)

Chair: M. Vonk (Nijmegen, The Netherlands)

#### PO13:107 EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS OVERLAP RHEUMATOID ARTHRITIS: PRELIMINARY DATA FROM A MONOCENTRIC, PROSPECTIVE, OPEN-LABEL STUDY

M. De Pinto, A. Spinella, L. Gavioli, G. Amati, A. Rai, F. Goatelli, P. Macripò, F. Lumetti, G. Sandri, O. Secchi, C. Salvarani, D. Giuggioli  
(Modena, Italy)

#### PO13:108 MANAGEMENT OF LUPUS NEPHRITIS: EXPERIENCE OF A SINGLE CENTER

R. Santangeli, S. Salvucci, G. Montozzi, L. Gamba, C. Cocco, P. Fioretti, L. Manfredi, G. Moroncini  
(Ancona, Italy)

#### PO13:109 THE REAL LIFE EXPERIENCE OF AN ITALIAN REFERRAL CENTER FOR RARE LUNG DISEASES: ANTIFIBROTIC DATA FROM 2018 TO PRESENT, PROGRESSIVE PULMONARY FIBROSIS AND THE USE OF CRYOBIOPSY

L. Gori, A. Sorano, G. Acquati, M. Amendola, C. Piccioli, D. Cozzi, E. Cavigli, C. Comin, P. Parronchi, V. Pasini, E. Vivarelli, S. Guiducci, F. Lavorini, S. Tomassetti, E. Rosi  
(Florence, Italy)

#### PO13:110 SEVERE INFECTIONS IN SLE PATIENTS: A DESCRIPTIVE ANALYSIS FROM A SINGLE CENTRE

G. Montozzi, S. Salvucci, L. Gamba, R. Santangeli, C. Cocco, P. Fioretti, L. Manfredi, G. Moroncini  
(Ancona, Italy)

#### PO13:111 IGG4-RELATED DISEASE: ANALYSIS OF RESPONDER INDEX REDUCTION ACCORDING TO TREATMENT IN A MONOCENTRIC COHORT OF PATIENTS

S. Bertocchi, F. Regola, C. Nalli, P. Toniati, L. Andreoli, I. Cavazzana, P. Airò, F. Franceschini  
(Brescia, Italy)

#### PO13:112 SAFETY AND EFFICACY OF B-CELL DEPLETION WITH RITUXIMAB FOR THE TREATMENT OF SYSTEMIC SCLEROSIS: AN UPDATE FROM OUR REAL-LIFE CLINICAL SETTING

A. Spinella, M. De Pinto, R. Greco, G. Amati, F. Lumetti, G. Sandri, O. Secchi, C. Salvarani, D. Giuggioli  
(Modena, Italy)

**PO13:113 ULTRASOUND-DETECTED EROSIONS COULD PREDICT THE EFFICACY OF BELIMUMAB IN ARTICULAR SYSTEMIC LUPUS ERYTHEMATOSUS**

R. Bixio, G. Orsolini, F. Mastropaoletti, E. Favaro, A. Piccinelli, O. Viapiana, M. Rossini  
(Verona, Italy)

**PO13:114 BARICITINIB AS ADJUVANT TREATMENT OF ANTI-NPX2 JUVENILE DERMATOMYOSITIS**

E. Marrani, S. Abu Rumeileh, V. Maniscalco, M.V. Mastrolia, I. Maccora, I. Pagnini, G. Simonini  
(Florence, Italy)

**PO13:115 CHARACTERISTICS OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS INITIATING BIOLOGIC THERAPY**

M. Tamas, I. Mihus, D. Bilous, C. Pamfil, I. Felea, L. Damian, L. Muntean, I. Filipescu, I. Szabo, S.P. Simon,  
C. Marinescu, S. Rednic  
(Cluj-Napoca, Romania)

**PO13:116 RECOMBINANT HUMAN HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN FOR IDIOPATHIC INFLAMMATORY MYOSITIS: A MULTICENTER OBSERVATIONAL STUDY**

A. Palermo<sup>1</sup>, A. Bettoli<sup>1</sup>, M.L. Urban<sup>1</sup>, A. Barilaro<sup>1</sup>, M.G. Danieli<sup>2</sup>, M. Capassoni<sup>1</sup>, S. Guiducci<sup>1</sup>, C. Campochiaro<sup>3</sup>,  
L. Dagna<sup>3</sup>, V. Canti<sup>3</sup>, P. Rovere-Querini<sup>3</sup>, C. Cardelli<sup>4</sup>, M. Mosca<sup>4</sup>, G. Emmi<sup>1</sup>  
(<sup>1</sup>Florence, Italy, <sup>2</sup>Ancona, Italy, <sup>3</sup>Milan, Italy, <sup>4</sup>Pisa, Italy)

**PO13:117 ASEPTIC ABSCESSSES SYNDROME: A CASE REPORT**

F.M. Ucci, C. Alessandri, R. Scrivo, F. Conti, R. Priori  
(Rome, Italy)

**PO13:118 THE ROLE OF HYDROXYCHLOROQUINE IN PREGNANT WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

A.B. De Almeida, J. Braga, A. Braga  
(Porto, Portugal)



## Important Dates

Abstract submission deadline:	<del>November 15<sup>th</sup> 2022</del> <b>November 20<sup>th</sup> 2022</b>
Abstract notification:	December 9 <sup>th</sup> 2022
Early registration deadline:	December 15 <sup>th</sup> 2022
Late registration deadline:	April 6 <sup>th</sup> 2023
Onsite registration:	From April 7 <sup>th</sup> 2023 and onsite

## Abstract submission

Participants interested in making an oral or poster presentation are invited to submit an abstract. All abstracts will undergo review by the Abstract Review Committee, to determine which abstracts may be accepted. To submit your abstract please [click here](#) and register.

Notification on acceptance of the abstracts will be e-mailed by December 9<sup>th</sup>, 2022. For each abstract, an author is expected to attend the congress and present the poster or oral communication. According to the congress registration policy, the Presenting Author of an accepted abstract must register within the registration deadline (December 15th, 2022) and attend the event. Registration is therefore mandatory in order to present an abstract during the Congress. Furthermore, the abstracts whose presenting author won't attend the event, will not be published on the final programme.

## Oral Communications and Posters

The Scientific Committee will select the abstracts in order to allocate them in the sessions as oral presentations or posters. Notification of acceptance or rejection will be sent to the corresponding author by **December 9<sup>th</sup>, 2022**. The presenting author of the accepted abstract must register and attend the Congress. More information about the abstract submission and guidelines are available at the following link:  
<https://www.ern-reconnectcongress.com/abstract>

## Oral Communications

Participants presenting oral sessions are requested to bring their presentation on a jump drive or laptop and arrive at the slide center room at least one hour before the session begins.

Each presentation should last no more than 7 minutes + 3 minutes for the discussion.

## Posters

All posters must have maximum dimensions of 70cm x 100 cm (vertical orientation).

Poster boards will be set up in a dedicated area of the Congress venue and must remain up for the all length of the Congress, so that participants will be able to view them at their convenience.

The presenter of each poster is kindly asked to remain close to the poster area in the following slots:

Posters from n. 1 to n. 30 will be held on Thursday, April 20th from h. 15:55 to 16:15

Posters from n. 31 to n. 118 will be held on Friday, April 21st from h. 10:50 to 11:40

Each presentation should last no more than 3 minutes and be very concise. A general discussion will be handled by the chair at the end of all poster presentations.

## Best posters

The best posters presented by authors under 35 will receive a prize during the Closing Ceremony.

The selection will be done by the Chairs during the Congress.



### UEMS Accreditation

The 1<sup>st</sup> ERN ReCONNECT International Congress on rare and low-prevalence connective tissue and musculoskeletal diseases, BRUSSELS, Belgium, 20/04/2023-22/04/2023 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 12 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

### CME Provider

#### AIM Education - Provider n. 93

Via G. Ripamonti, 129 – 20141 Milan, Italy

T +39 02 56601.1

cme@aimgroup.eu - [www.aimeducation.it](http://www.aimeducation.it)  
[www.ern-reconnectcongress.com/cme-credits](http://www.ern-reconnectcongress.com/cme-credits)



## Congress Venue

**DoubleTree by Hilton Brussels City**  
Rue Gineste, 3  
1210 Brussels (Belgium)



## How to reach the Congress Venue

### From Brussels Central Station

The closest railway station is Brussels-North station which is just 500 m away (about 6 min by foot) from the venue. If you are going to depart from the central railway station, it's possible to:

- Take a taxi (total expected time: 8 minutes)
- Take a train to Brussels-North station (main train lines: IC, S2, S10) and then walk to the venue (total expected time: 10 minutes)
- Take a bus to Arenberg (main bus lines: 29/71) and then walk to the venue (total expected time: 14 minutes)
- Take a tram from Palais (5 min-walk from the station) to Botanique (main tram lines: 92/93) and then walk for about 5 minutes to the venue (total expected time: 15 minutes)
- Walk for 1,3 km (total expected time: 16 minutes)



### From Brussels International Airport

The International Airport is only a 20-minute taxi ride away from the venue. Otherwise, it's possible to:

- Take the IC train to Brussels-North station and then walk to the venue (total expected time: 20 minutes)
- Take the 471 bus from Zaventem Luchthaven perron A to Brussel Noord afstaphalte and then walk for about 6 minutes (total expected time: 40 minutes)



European  
Reference  
Network

# ReCONNECT

General and Scientific Information

## Organizing Secretariat



AIM Italy - Milan Office  
Via G. Ripamonti, 129 – 20141 Milan, Italy  
T +39 02 566011  
<https://www.ern-reconnectcongress.com/>  
general information: ern.reconnectcongress@aimgroup.eu

## Secretariat and Registration Desk

The on-site registration desks will be open during the following days:

- Thursday, 20 April 2023 12:00 – 19:30
- Friday, 21 April 2023 08:30 – 18:00
- Saturday, 22 April 2023 08:00 – 14:30

## Admission

Participants are kindly requested to wear their badge during all congress activities.  
The badge will allow you to access the scientific sessions, coffee breaks and lunches.

## Opening Ceremony and Welcome Cocktail

The Opening Ceremony of the Congress will be held on April 20 at 13.00 at the Sycamore Ballroom.  
At the end of the scientific sessions, at 18:35, a Networking Cocktail will follow.

## Local PCO



AIM Group Belgium BVBA  
Greenstraat 7 – B-1831 Diegem, Belgium  
T +32 27228230  
brussels@aimgroup.eu

## Language

The official language is English. No simultaneous translation will be provided.

## Attendance Certificates

Attendance certificates will be delivered to all regularly registered participants after the meeting.

## Accommodation

At the DoubleTree by Hilton Brussels City a room block has been secured for congress delegates at a discounted rate (125€).

Should you be interested in reserving a room, kindly contact the Organizing Secretariat ([ern.reconnectcongress@aimgroup.eu](mailto:ern.reconnectcongress@aimgroup.eu)).

*Please note that accessible rooms for wheelchairs users are no longer available.*

## Visa Requirements

All non-Belgian nationals entering Belgium must provide valid travel documentation. Delegates who hold neither an EU passport nor a Schengen visa should check as soon as possible the Belgian Ministry of Foreign Affairs' website to see if they require a visa to enter Belgium.

Visa regulations depend on your nationality and country of origin. For the most updated information regarding visa requirements, we do suggest you contact your local consulate for full and official instructions on the specific visa regulations and application procedures that apply to you.

If a visa is required, delegates should apply to the Belgian Diplomatic and Consular Representations in their country of residence with the documents outlined on the Ministry of Foreign Affairs' website.

*Please Note:* Visa applications may take several months. Please check this now.

Visa application fees vary. Please contact the embassy or consulate in order to enquire about costs.

Presentation of the requested documentation does not guarantee that the visa will be issued.

AIM Group will be glad to assist you if you need any other written invitation or other document to support your visa application at the following e-mail address: [visa@aimgroup.eu](mailto:visa@aimgroup.eu)

## Invitation Letter

The Official Invitation letter to be included in your application to enter Belgium can be downloaded from the registration area of our website. If you did not submit your personal data yet, click on "First time user" and fill in the submission form. Once you finish to fill in the personal data form, click on "Invitation Letter (VISA)" on the left side menu. If you already submitted your personal data, log in (using your User ID and Password) and click on "Edit your personal data" to insert the passport details, at the end click on "Invitation Letter (VISA)" from the left side menu. The Invitation Letter will not be legally or financially binding on the Organizing Secretariat. Expenses related to the conference shall be born by delegates themselves.

## Registrations (All fees are 21% VAT included)

	within December 15 <sup>th</sup> 2022	within April 6 <sup>th</sup> 2023	From April 7 <sup>th</sup> 2023 and onsite
Delegate member ERN*		€ 250,00  (the fee for ERN members is not subject to any increase. It covers running costs such as catering services and conference materials)	
Delegate NON member ERN	€ 350,00	€ 400,00	€ 450,00
Students/Trainees**	€ 150,00	€ 200,00	€ 250,00
Healthcare professional***		€ 150,00	
Patients****		€ 50,00	

\* ERN ReCONNECT is pleased to offer each centre all the following:

- 1 free registration for the Congress for one person;
- a 2-night stay in hotel covered by ERN during the Congress days (April 20-22) for one person;
- travel expenses covered by ERN up to a total amount of 200 € for one person.

\*\* In order to benefit from the special fee, a submission of your status confirmation must be uploaded online during the registration process (i.e. approval letter signed by the Head of Department or copy of your status ID).

\*\*\* Nurses, physiotherapists, occupational therapists and other nearby allied health professionals. A letter of confirmation of your status from the Head of Unit or Institute must accompany and uploaded in the online registration.

\*\*\*\* Patients registering at this fee must upload a proof of their status declaration by a doctor or a proof of their membership of a Patient Association during the registration process. If no certificate is being uploaded, the registration process cannot be completed. Please note that you might not have access to industry sponsored satellite symposia.

**Online Services will close on: 10 April 2023**

### The Delegate Fee Includes:

- Admission to the scientific sessions
- Congress bag holding all the meeting materials
- Certificate of attendance
- Access to the poster area
- Coffee breaks and lunches, according to the programme
- Networking cocktail on April 20<sup>th</sup>



### Payment

All major credit cards are accepted (VISA, Mastercard/Eurocard, American Express).

If you decide to pay by bank transfer, please remind to clearly state the name(s) of the delegate(s) and of the event "ERN ReConnect 2023".

Registration will be considered confirmed when the payment is received. An invoice will follow.

### Name Changes

After March 30<sup>th</sup> 2023 sponsors who wish to make name changes will be charged of an handling fee of € 50,00 (VAT 21% included) per name change. A new registration form for each replacement participant will be required before the name change can be processed. Individuals may make name changes only in exceptional cases.

### Cancellation Policy

Notification of cancellation must be sent in writing to  
AIM GROUP INTERNATIONAL [ern.reconnectcongress@aimgroup.eu](mailto:ern.reconnectcongress@aimgroup.eu)

Cancellations will be accepted until March 30<sup>th</sup>, 2023, with a refund of all prepaid fees except for a 30% administration charge. No refunds will be made for cancellations received after this date.

